Norepinephrine–dopamine reuptake inhibitor

Further information: Norepinephrine reuptake inhibitor and Dopamine reuptake inhibitor
Norepinephrine–dopamine reuptake inhibitor
Drug class
Methylphenidate, one of the most widely used NDRIs.
Class identifiers
UseADHD, depression, narcolepsy
Mechanism of actionreuptake inhibitor
Biological targetnorepinephrine transporter (NET),
dopamine transporter (DAT)
Legal status
In Wikidata

A norepinephrine–dopamine reuptake inhibitor (NDRI) is a type of drug that inhibits the reuptake of the monoamine neurotransmitters norepinephrine and dopamine and thereby increases extracellular levels of these neurotransmitters and noradrenergic and dopaminergic neurotransmission.[1] They work by competitively and/or noncompetitively inhibiting the norepinephrine transporter (NET) and dopamine transporter (DAT).[1]

NDRIs are used clinically in the treatment of conditions including attention deficit hyperactivity disorder (ADHD), narcolepsy, and depression. Examples of well-known NDRIs include methylphenidate and bupropion.

A closely related type of drug is a norepinephrine–dopamine releasing agent (NDRA).

  1. ^ a b Stephen M. Stahl (2 March 2009). Antidepressants. Cambridge University Press. p. 73. ISBN 978-0-521-75852-9. Retrieved 10 May 2012.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.